Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
1.
Elife ; 72018 03 16.
Article in English | MEDLINE | ID: mdl-29547122

ABSTRACT

Ribosomal proteins (RPs) play important roles in modulating the MDM2-p53 pathway. However, less is known about the upstream regulators of the RPs. Here, we identify SPIN1 (Spindlin 1) as a novel binding partner of human RPL5/uL18 that is important for this pathway. SPIN1 ablation activates p53, suppresses cell growth, reduces clonogenic ability, and induces apoptosis of human cancer cells. Mechanistically, SPIN1 sequesters uL18 in the nucleolus, preventing it from interacting with MDM2, and thereby alleviating uL18-mediated inhibition of MDM2 ubiquitin ligase activity toward p53. SPIN1 deficiency increases ribosome-free uL18 and uL5 (human RPL11), which are required for SPIN1 depletion-induced p53 activation. Analysis of cancer genomic databases suggests that SPIN1 is highly expressed in several human cancers, and its overexpression is positively correlated with poor prognosis in cancer patients. Altogether, our findings reveal that the oncogenic property of SPIN1 may be attributed to its negative regulation of uL18, leading to p53 inactivation.


Subject(s)
Carcinogenesis/genetics , Cell Cycle Proteins/genetics , Microtubule-Associated Proteins/genetics , Phosphoproteins/genetics , Proto-Oncogene Proteins c-mdm2/genetics , Ribosomal Proteins/genetics , Tumor Suppressor Protein p53/genetics , Animals , Carcinogenesis/metabolism , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cell Proliferation/genetics , Cells, Cultured , Gene Expression Regulation, Neoplastic , HCT116 Cells , HEK293 Cells , Humans , Mice , Microtubule-Associated Proteins/metabolism , Neoplasms/genetics , Neoplasms/metabolism , Neoplasms/pathology , Phosphoproteins/metabolism , Proto-Oncogene Proteins c-mdm2/metabolism , Ribosomal Proteins/metabolism , Ribosome Subunits, Large, Eukaryotic/genetics , Ribosome Subunits, Large, Eukaryotic/metabolism , Signal Transduction/genetics , Tumor Suppressor Protein p53/metabolism
2.
Elife ; 52016 07 07.
Article in English | MEDLINE | ID: mdl-27383270

ABSTRACT

Increasing evidence highlights the important roles of microRNAs in mediating p53's tumor suppression functions. Here, we report miR-139-5p as another new p53 microRNA target. p53 induced the transcription of miR-139-5p, which in turn suppressed the protein levels of phosphodiesterase 4D (PDE4D), an oncogenic protein involved in multiple tumor promoting processes. Knockdown of p53 reversed these effects. Also, overexpression of miR-139-5p decreased PDE4D levels and increased cellular cAMP levels, leading to BIM-mediated cell growth arrest. Furthermore, our analysis of human colorectal tumor specimens revealed significant inverse correlation between the expression of miR-139-5p and that of PDE4D. Finally, overexpression of miR-139-5p suppressed the growth of xenograft tumors, accompanied by decrease in PDE4D and increase in BIM. These results demonstrate that p53 inactivates oncogenic PDE4D by inducing the expression of miR-139-5p.


Subject(s)
Cyclic Nucleotide Phosphodiesterases, Type 4/biosynthesis , Gene Expression Regulation, Neoplastic , MicroRNAs/metabolism , Tumor Suppressor Protein p53/metabolism , Animals , Cell Line, Tumor , Colorectal Neoplasms/pathology , Disease Models, Animal , Heterografts , Humans , Mice, Inbred BALB C
3.
Sci Rep ; 6: 23542, 2016 Mar 23.
Article in English | MEDLINE | ID: mdl-27005522

ABSTRACT

Tumor suppressor p53 transcriptionally regulates hundreds of genes involved in various cellular functions. However, the detailed mechanisms underlying the selection of p53 targets in response to different stresses are still elusive. Here, we identify TFIIS.h, a transcription elongation factor, as a new transcriptional target of p53, and also show that it can enhance the efficiency of transcription elongation of apoptosis-associated bax gene, but not cell cycle-associated p21 (CDKN1A) gene. TFIIS.h is revealed as a p53 target through microarray analysis of RNAs extracted from cells treated with or without inauhzin (INZ), a p53 activator, and further confirmed by RT-q-PCR, western blot, luciferase reporter, and ChIP assays. Interestingly, knocking down TFIIS.h impairs, but overexpressing TFIIS.h promotes, induction of bax, but not other p53 targets including p21, by p53 activation. In addition, overexpression of TFIIS.h induces cell death in a bax- dependent fashion. These findings reveal a mechanism by which p53 utilizes TFIIS.h to selectively promote the transcriptional elongation of the bax gene, upsurging cell death in response to severe DNA damage.


Subject(s)
Stomach Neoplasms/genetics , Transcriptional Elongation Factors/genetics , Transcriptional Elongation Factors/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , bcl-2-Associated X Protein/genetics , Cell Survival , Down-Regulation , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , HCT116 Cells , Humans , Indoles/pharmacology , Oligonucleotide Array Sequence Analysis/methods , Phenothiazines/pharmacology , Promoter Regions, Genetic , Transcription, Genetic
4.
J Mol Cell Biol ; 7(2): 92-104, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25735597

ABSTRACT

Although ribosomal proteins are known for playing an essential role in ribosome assembly and protein translation, their ribosome-independent functions have also been greatly appreciated. Over the past decade, more than a dozen of ribosomal proteins have been found to activate the tumor suppressor p53 pathway in response to ribosomal stress. In addition, these ribosomal proteins are involved in various physiological and pathological processes. This review is composed to overview the current understanding of how ribosomal stress provokes the accumulation of ribosome-free ribosomal proteins, as well as the ribosome-independent functions of ribosomal proteins in tumorigenesis, immune signaling, and development. We also propose the potential of applying these pieces of knowledge to the development of ribosomal stress-based cancer therapeutics.


Subject(s)
Ribosomal Proteins/physiology , Animals , Humans , Neoplasms/metabolism , Oncogene Proteins/physiology , Organ Specificity , Signal Transduction , Tumor Suppressor Proteins/physiology
5.
Cancer Biol Ther ; 16(3): 412-9, 2015.
Article in English | MEDLINE | ID: mdl-25692307

ABSTRACT

Oncogene MYC is deregulated in many human cancers, especially in lymphoma. Previously, we showed that inauhzin (INZ) activates p53 and inhibits tumor growth. However, whether INZ could suppress cancer cell growth independently of p53 activity is still elusive. Here, we report that INZ(c), a second generation of INZ, suppresses c-Myc activity and thus inhibits growth of human lymphoma cells in a p53-independent manner. INZ(c) treatment decreased c-Myc expression at both mRNA and protein level, and suppressed c-Myc transcriptional activity in human Burkitt's lymphoma Raji cells with mutant p53. Also, we showed that overexpressing ectopic c-Myc rescues the inhibition of cell proliferation by INZ(c) in Raji cells, implicating c-Myc activity is targeted by INZ(c). Interestingly, the effect of INZ(c) on c-Myc expression was impaired by disrupting the targeting of c-Myc mRNA by miRNAs via knockdown of ribosomal protein (RP) L5, RPL11, or Ago2, a subunit of RISC complex, indicating that INZ(c) targets c-Myc via miRNA pathways. These results reveal a new mechanism that INZ


Subject(s)
Burkitt Lymphoma/drug therapy , Indoles/administration & dosage , Phenothiazines/administration & dosage , Proto-Oncogene Proteins c-myc/biosynthesis , Tumor Suppressor Protein p53/biosynthesis , Apoptosis/drug effects , Argonaute Proteins/biosynthesis , Burkitt Lymphoma/genetics , Burkitt Lymphoma/pathology , Cell Proliferation/drug effects , Gene Expression Regulation, Leukemic , Humans , Proto-Oncogene Proteins c-myc/genetics , RNA, Messenger/biosynthesis , Ribosomal Proteins/biosynthesis , Signal Transduction/drug effects , Tumor Suppressor Protein p53/genetics
6.
Eur J Pharmacol ; 738: 125-32, 2014 Sep 05.
Article in English | MEDLINE | ID: mdl-24877694

ABSTRACT

Novel influenza A H7N9 virus, which emerged in 2013, and highly pathogenic H5N1 virus, identified since 2003, pose challenges to public health and necessitate quest for new anti-influenza compounds. Anthraquinone derivatives like aloe-emodin, emodin and chrysophanol, reportedly exhibit antiviral activity. This study probes their inhibitory mechanism and effect against influenza A virus. Of three anthraquinone derivatives, aloe-emodin, with a lower cytotoxicity showed concentration-dependently reducing virus-induced cytopathic effect and inhibiting replication of influenza A in MDCK cells. 50% inhibitory concentration value of aloe-emodin on virus yield was less than 0.05 µg/ml. Proteomics and Western blot of MDCK cells indicated aloe-emodin up-regulating galectin-3, and thioredoxin as well as down-regulating nucleoside diphosphate kinase A. Western blot and quantitative PCR confirmed aloe-emodin up-regulating galectin-3 expression; recombinant galectin-3 augmented expression of antiviral genes IFN-ß, IFN-γ, PKR and 2'5',-OAS in infected cells, agreeing with expression pattern of those treated with aloe-emodin. Galectin-3 also inhibited influenza A virus replication. Proteomic analysis of treated cells indicated galectin-3 up-regulation as one anti-influenza A virus action by aloe-emodin. Since galectin-3 exhibited cytokine-like regulatory actions via JAK/STAT pathways, aloe-emodin also restored NS1-inhibited STAT1-mediated antiviral responses in transfected cells: e.g., STAT1 phosphorylation of interferon (IFN) stimulation response element (ISRE)-driven promoter, RNA-dependent protein kinase (PKR) and 2'5',-oligoadenylate synthetase (2'5',-OAS) expression. Treatment with aloe-emodin could control influenza infection in humans.


Subject(s)
Anthraquinones/pharmacology , Antiviral Agents/pharmacology , Galectin 3/genetics , Influenza A virus/drug effects , Up-Regulation/drug effects , Animals , Dogs , Humans , Influenza A virus/physiology , Interferon Type I/pharmacology , JNK Mitogen-Activated Protein Kinases/metabolism , Madin Darby Canine Kidney Cells , Proteomics , STAT Transcription Factors/metabolism , Signal Transduction/drug effects , Viral Nonstructural Proteins/antagonists & inhibitors , Viral Nonstructural Proteins/genetics , Virus Replication/drug effects
7.
J Mol Cell Biol ; 6(3): 206-13, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24740682

ABSTRACT

The tumor suppressor p53 pathway, whose alterations are highly associated with all types of human cancers, plays an essential role in preventing tumor development and progression mostly through its downstream target genes. Over the last decade, a growing list of p53 microRNA (miRNA) targets has been identified as additional downstream players of this pathway. Further studies of these miRNAs have revealed their more complicated regulations and functions in executing and/or regulating p53 activity. Here, we review the p53 miRNA targets identified thus far, and discuss how they fine-tune p53 stress responses, mediate the crosstalk between p53 and other signaling pathways, and expand the role of p53 in other human diseases in addition to cancers.


Subject(s)
MicroRNAs/metabolism , Tumor Suppressor Protein p53/metabolism , Animals , Apoptosis/genetics , Cell Cycle Checkpoints/genetics , Humans , MicroRNAs/genetics , Neoplasms/genetics , Neoplasms/pathology , Signal Transduction , Tumor Suppressor Protein p53/genetics
8.
J Biol Chem ; 288(30): 21793-801, 2013 Jul 26.
Article in English | MEDLINE | ID: mdl-23775087

ABSTRACT

The ribosomal gene RPS14 is associated with the cancer-prone 5q-syndrome, which is caused by an interstitial deletion of the long arm of human chromosome 5. Previously, we found that ribosomal protein S14 (RPS14) binds to and inactivates MDM2, consequently leading to p53-dependent cell-cycle arrest and growth inhibition. However, it remains elusive whether RPS14 regulates cell proliferation in a p53-independent manner. Here, we show that RPS14 interacts with the Myc homology box II (MBII) and the C-terminal basic helix-loop-helix leucine zipper (bHLH-LZ) domains of the oncoprotein c-Myc. Further, RPS14 inhibited c-Myc transcriptional activity by preventing the recruitment of c-Myc and its cofactor, TRRAP, to the target gene promoters, as thus suppressing c-Myc-induced cell proliferation. Also, siRNA-mediated RPS14 depletion elevated c-Myc transcriptional activity determined by its target gene, Nucleolin, expression. Interestingly, RPS14 depletion also resulted in the induction of c-Myc mRNA and subsequent protein levels. Consistent with this, RPS14 promoted c-Myc mRNA turnover through an Argonaute 2 (Ago2)- and microRNA-mediated pathway. Taken together, our study demonstrates that RPS14 negates c-Myc functions by directly inhibiting its transcriptional activity and mediating its mRNA degradation via miRNA.


Subject(s)
Gene Expression Regulation, Neoplastic , Proto-Oncogene Proteins c-myc/genetics , Ribosomal Proteins/genetics , Signal Transduction/genetics , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Argonaute Proteins/genetics , Argonaute Proteins/metabolism , Binding Sites/genetics , Cell Line, Tumor , HCT116 Cells , Humans , Immunoblotting , MicroRNAs/genetics , MicroRNAs/metabolism , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Phosphoproteins/genetics , Phosphoproteins/metabolism , Promoter Regions, Genetic/genetics , Protein Binding , Proto-Oncogene Proteins c-myc/metabolism , RNA Interference , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Ribosomal Proteins/metabolism , Transcriptional Activation , Nucleolin
9.
J Biol Chem ; 288(25): 18184-93, 2013 Jun 21.
Article in English | MEDLINE | ID: mdl-23589370

ABSTRACT

Previously, we reported that IκB kinase-ß(IKKß) phosphorylates and stabilizes TAp63γ. However, the effect of this phosphorylation on TAp63γ transcriptional activity remains unclear. In this study, we showed that overexpression of IKKß, but not its kinase dead mutant and IKKα, can surprisingly inhibit TAp63γ transcriptional activity as measured by luciferase assays and real-time PCR analyses of p63 target genes. This inhibition was impaired by ACHP, an IKKß inhibitor, and enhanced by TNFα that activates IKKß. Consistently, IKKß inhibited the binding between TAp63γ and p300, a co-activator of TAp63γ, and consequently counteracted the positive effect of p300 on TAp63γ transcriptional activity. Through phosphorylation site prediction and mass spectrometry, we identified that Ser-4 and Ser-12 of p63 are IKKß-targeting residues. As expected, IKKß fails to suppress the transcriptional activity of the S4A/S12A double mutant p63. These results indicate that IKKß can suppress TAp63γ activity by interfering with the interaction between TAp63γ and p300.


Subject(s)
E1A-Associated p300 Protein/metabolism , I-kappa B Kinase/metabolism , Transcription Factors/metabolism , Transcriptional Activation , Tumor Suppressor Proteins/metabolism , Binding Sites/genetics , Blotting, Western , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p21/genetics , E1A-Associated p300 Protein/genetics , Gene Expression , Humans , I-kappa B Kinase/antagonists & inhibitors , I-kappa B Kinase/genetics , MicroRNAs/genetics , Mutation , Nicotinic Acids/pharmacology , Nitriles/pharmacology , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Isoforms/genetics , Protein Isoforms/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Serine/genetics , Serine/metabolism , Transcription Factors/genetics , Transfection , Tumor Necrosis Factor-alpha/pharmacology , Tumor Suppressor Proteins/genetics
10.
Methods Mol Biol ; 962: 201-10, 2013.
Article in English | MEDLINE | ID: mdl-23150449

ABSTRACT

Chromatin immunoprecipitation assay (ChIP) has been frequently used to determine whether a transcriptional regulator can bind to a specific DNA element in the chromatin content of cells. Here, we describe a detailed protocol for this assay with hands-on tips based on our own experience in working on the transcriptional regulator and tumor suppressor p53.


Subject(s)
Chromatin Immunoprecipitation/methods , DNA/genetics , Promoter Regions, Genetic , Tumor Suppressor Protein p53/genetics , Cell Line, Tumor , DNA/metabolism , DNA Fragmentation , Gene Expression Regulation , Humans , Protein Binding/genetics , Transcription, Genetic
11.
Genes Cancer ; 3(3-4): 298-310, 2012 Mar.
Article in English | MEDLINE | ID: mdl-23150763

ABSTRACT

The oncoprotein MDM2 is both the transcriptional target and the predominant antagonist of the tumor suppressor p53. MDM2 inhibits the functions of p53 via a negative feedback loop that can be circumvented by several ribosomal proteins in response to nucleolar or ribosomal stress. Stress conditions in the nucleolus can be triggered by a variety of extracellular and intracellular insults that impair ribosomal biogenesis and function, such as chemicals, nutrient deprivation, DNA damaging agents, or genetic alterations. The past decade has witnessed a tremendous progress in understanding this previously underinvestigated ribosomal stress-MDM2-p53 pathway. Here, we review the recent progress in understanding this unique signaling pathway, discuss its biological and pathological significance, and share with readers our insight into the research in this field.

12.
Cell Cycle ; 11(14): 2624-30, 2012 Jul 15.
Article in English | MEDLINE | ID: mdl-22751441

ABSTRACT

Since the discovery of miRNAs, a number of miRNAs have been identified as p53's transcriptional targets. Most of them are involved in regulation of the known p53 functions, such as cell cycle, apoptosis and senescence. Our recent study revealed miR-1246 as a novel target of p53 and its analogs p63 and p73 to suppress the expression of DYRK1A and consequently activate NFAT, both of which are associated with Down syndrome and possibly with tumorigenesis. This finding suggests that miR-1246 might serve as a likely link of the p53 family with Down syndrome. Here, we provide some prospective views on the potential role of the p53 family in Down syndrome via miR-1246 and propose a new p53-miR-1246-DYRK1A-NFAT pathway in cancer.


Subject(s)
Down Syndrome/metabolism , MicroRNAs/metabolism , Neoplasms/metabolism , Tumor Suppressor Protein p53/metabolism , Apoptosis , Cell Line, Tumor , Chromosome Aberrations , Down Syndrome/pathology , Female , Humans , Male , NFATC Transcription Factors/metabolism , Neoplasms/pathology , Polymorphism, Single Nucleotide , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Signal Transduction , Tumor Suppressor Protein p53/genetics , Dyrk Kinases
13.
PLoS One ; 7(12): e52172, 2012.
Article in English | MEDLINE | ID: mdl-23284922

ABSTRACT

BACKGROUND: Previously, we reported that Inauhzin (INZ) induces p53 activity and suppresses tumor growth by inhibiting Sirt1. However, it remains unknown whether INZ may globally affect p53-dependent gene expression or not. Herein, we have conducted microarray and real-time PCR analyses of gene expression to determine the global effect of INZ on human p53-responsive transcriptome. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we conducted microarray analysis followed by PCR validation of general gene expression in HCT116(p53+/+) and HCT116(p53-/-) cells treated with or without INZ. Microarray data showed that 324 genes were up-regulated by ≥ 2.3-fold and 266 genes were down-regulated by ≥ 2-fold in response to INZ treatment in a p53-dependent manner. GO analysis for these genes further revealed that INZ affects several biological processes, including apoptosis (GO:0006915), cell cycle (GO:0007049), immune system process (GO:0002376), and cell adhesion (GO:0007155), which are in line with p53 functions in cells. Also, pathway and STRING analyses of these genes indicated that the p53-signaling pathway is the most significant pathway responsive to INZ treatment as predicted, since a number of these p53 target genes have been previously reported and some of them were validated by RT-qPCR. Finally, among the 9 tested and highly expressed genes, ACBD4, APOBEC3C, and FLJ14327 could be novel p53 target genes, for they were up-regulated by INZ in HCT116(p53+/+) cells, but not in HCT116(p53-/-) cells. CONCLUSIONS/SIGNIFICANCE: From our whole genome microarray analysis followed by validation with RT-qPCR, we found that INZ can indeed induce the expression of p53 target genes at a larger scale or globally. Our findings not only verify that INZ indeed activates the p53 signaling pathway, but also provide useful information for identifying novel INZ and/or p53 targets. The global effect of INZ on human p53-responsive transcriptome could also be instrumental to the future design of INZ clinical trials.


Subject(s)
Indoles/pharmacology , Phenothiazines/pharmacology , Transcriptome/drug effects , Transcriptome/genetics , Tumor Suppressor Protein p53/metabolism , HCT116 Cells , Humans , Oligonucleotide Array Sequence Analysis , Polymerase Chain Reaction , Signal Transduction/drug effects , Signal Transduction/genetics , Tumor Suppressor Protein p53/genetics
14.
Protein Cell ; 2(11): 899-905, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22180089

ABSTRACT

Parkinson's disease is the second most common neurodegenerative disease in the world. Beta-arrestin-2 has been reported to be an important protein involved in D(2) dopamine receptor desensitization, which is essential to Parkinson's disease. Moreover, the potential value of pharmacological inactivation of G protein-coupled receptor kinase or arrestin in the treatment of patients with Parkinson's disease has recently been shown. We studied the interaction between D(2) dopamine receptor and beta-arrestin-2 and the pharmacological regulation of chemical compounds on such interaction using capillary zone electrophoresis. The results from screening more than 40 compounds revealed three compounds that remarkably inhibit the beta-arrestin-2/D(2) dopamine receptor interaction among them. These compounds are promising therapies for Parkinson's disease, and the method used in this study has great potential for application in large-scale drug screening and evaluation.


Subject(s)
Arrestins/metabolism , Dopamine Antagonists/therapeutic use , Drug Evaluation, Preclinical , Electrophoresis, Capillary , Parkinson Disease/drug therapy , Receptors, Dopamine D2/metabolism , Arrestins/antagonists & inhibitors , Dopamine/metabolism , Dopamine D2 Receptor Antagonists , Humans , Parkinson Disease/metabolism , Parkinson Disease/pathology , Signal Transduction , beta-Arrestin 2 , beta-Arrestins
15.
J Biol Chem ; 286(39): 33901-9, 2011 Sep 30.
Article in English | MEDLINE | ID: mdl-21832077

ABSTRACT

The expression of the c-myc oncogene at both protein and mRNA levels is transient and begins to be turned off 3-6 h after growth stimulation of cultured cells. The exact mechanism(s) underlying this down-regulation of c-Myc remains incompletely understood. Here we report the identification of miR-185-3p as a novel feedback regulator of c-Myc. This microRNA (miRNA) was initially identified as one of the c-Myc target miRNA transcripts through analysis of RNA samples isolated from cells prior to and after serum stimulation and further verified by real-time PCR, luciferase reporter, and ChIP assays. Interestingly, overexpression of wild type, but not mutant, miR-185-3p decreased the protein, but not mRNA, level of c-Myc in a dose-dependent fashion and also drastically abated the serum induction of c-Myc level in human cancer cells by targeting the coding sequence of c-Myc mRNA, consequently suppressing c-Myc-mediated proliferation. A miR-185-3p inhibitor rescued the inhibition of c-Myc expression by endogenous miR-185-3p. Thus, our results unveil miR-185-3p as the first miRNA that monitors c-Myc levels via an autoregulatory feedback mechanism in response to serum stimulation.


Subject(s)
Down-Regulation/physiology , MicroRNAs/metabolism , Proto-Oncogene Proteins c-myc/biosynthesis , RNA, Messenger/biosynthesis , Cell Line, Tumor , Humans , MicroRNAs/genetics , Mutation , Proto-Oncogene Proteins c-myc/genetics , RNA, Messenger/genetics
16.
PLoS One ; 6(7): e21929, 2011.
Article in English | MEDLINE | ID: mdl-21750741

ABSTRACT

BACKGROUND: Ras protein, as one of intracellular signal switches, plays various roles in several cell activities such as differentiation and proliferation. There is considerable evidence showing that calmodulin (CaM) binds to K-RasB and dissociates K-RasB from membrane and that the inactivation of CaM is able to induce K-RasB activation. However, the mechanism for the interaction of CaM with K-RasB is not well understood. METHODOLOGY/PRINCIPAL FINDINGS: Here, by applying fluorescence spectroscopy and isothermal titration calorimetry, we have obtained thermodynamic parameters for the interaction between these two proteins and identified the important elements of K-RasB for its interaction with Ca(2+)/CaM. One K-RasB molecule interacts with one CaM molecule in a GTP dependent manner with moderate, micromolar affinity at physiological pH and physiologic ionic strength. Mutation in the polybasic domain of K-Ras decreases the binding affinity. By using a chimera in which the C-terminal polylysine region of K-RasB has been replaced with that of H-Ras and vice versa, we find that at physiological pH, H-Ras-(KKKKKK) and Ca(2+)/CaM formed a 1:1 complex with an equilibrium association constant around 10(5) M(-1), whereas no binding reaction of K-RasB-(DESGPC) with Ca(2+)/CaM is detected. Furthermore, the interaction of K-RasB with Ca(2+)/CaM is found to be enhanced by the farnesylation of K-RasB. CONCLUSIONS/SIGNIFICANCE: We demonstrate that the polylysine region of K-RasB not only contributes importantly to the interaction of K-RasB with Ca(2+)/CaM, but also defines its isoform specific interaction with Ca(2+)/CaM. The farnesylation of K-RasB is also important for its specific interaction with Ca(2+)/CaM. Information obtained here can enhance our understanding of how CaM interacts with K-RasB in physiological environments.


Subject(s)
Calcium/metabolism , Calmodulin/metabolism , Polylysine/metabolism , Proto-Oncogene Proteins p21(ras)/metabolism , Algorithms , Amino Acid Sequence , Animals , Blotting, Western , Calcium/chemistry , Calmodulin/chemistry , Calmodulin/genetics , Calorimetry , Cattle , Escherichia coli/genetics , Kinetics , Light , Models, Chemical , Polylysine/chemistry , Polylysine/genetics , Prenylation , Protein Binding/radiation effects , Proto-Oncogene Proteins p21(ras)/chemistry , Proto-Oncogene Proteins p21(ras)/genetics , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Spectrometry, Fluorescence , Thermodynamics
17.
EMBO Rep ; 12(8): 811-7, 2011 Jun 03.
Article in English | MEDLINE | ID: mdl-21637297

ABSTRACT

Several microRNAs mediate the functions of p53 family members. Here we characterize miR-1246 as a new target of this family. In response to DNA damage, p53 induces the expression of miR-1246 which, in turn, reduces the level of DYRK1A, a Down syndrome-associated protein kinase. Knockdown of p53 has the opposite effect. Overexpression of miR-1246 reduces DYRK1A levels and leads to the nuclear retention of NFATc1, a protein substrate of DYRK1A, and the induction of apoptosis, whereas a miR-1246-specific inhibitor prevented the nuclear import of NFATc1. Together, these results indicate that p53 inhibits DYRK1A expression through the induction of miR-1246.


Subject(s)
Down Syndrome/genetics , Down Syndrome/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Apoptosis/genetics , Cell Line, Tumor , DNA Damage/genetics , Down-Regulation , HCT116 Cells , Humans , MicroRNAs/antagonists & inhibitors , NFATC Transcription Factors/metabolism , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , Dyrk Kinases
18.
Biochim Biophys Acta ; 1784(11): 1560-9, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18790720

ABSTRACT

Both Ras protein and calcium play significant roles in various cellular processes via complex signaling transduction networks. However, it is not well understood whether and how Ca(2+) can directly regulate Ras function. Here we demonstrate by isothermal titration calorimetry that Ca(2+) directly binds to the H-Ras.GDP.Mg(2+) complex with moderate affinity at the first binding site followed by two weak binding events. The results from limited proteinase degradation show that Ca(2+) protects the fragments of H-Ras from being further degraded by trypsin and by proteinase K. HPLC studies together with fluorescence spectroscopic measurements indicate that binding of Ca(2+) to the H-Ras.GDP.Mg(2+) complex remarkably promotes guanine nucleotide exchange on H-Ras under emulated physiological Ca(2+) concentration conditions. Addition of high concentrations of either of two macromolecular crowding agents, Ficoll 70 and dextran 70, dramatically enhances H-Ras guanine nucleotide exchange extent in the presence of Ca(2+) at emulated physiological concentrations, and the nucleotide exchange extent increases significantly with the concentrations of crowding agents. Together, these results indicate that binding of calcium ions to H-Ras remarkably promotes H-Ras guanine nucleotide exchange under emulated physiological conditions. We thus propose that Ca(2+) may activate Ras signaling pathway by interaction with Ras, providing clues to understand the role of calcium in regulating Ras function in physiological environments.


Subject(s)
Calcium/metabolism , Guanine Nucleotides/metabolism , ras Proteins/metabolism , ras Proteins/physiology , Amino Acid Sequence , Binding Sites , Calcium/pharmacology , Computer Simulation , Dose-Response Relationship, Drug , Humans , Ions/metabolism , Models, Biological , Molecular Sequence Data , Osmolar Concentration , Protein Binding/drug effects , Signal Transduction/physiology
19.
Int J Biochem Cell Biol ; 38(11): 1986-94, 2006.
Article in English | MEDLINE | ID: mdl-16857407

ABSTRACT

Physiological medium constitutes a crowded environment that serves as the field of action for protein-protein interaction in vivo. Measuring protein-protein interaction in crowded solutions can mimic this environment. Here we report the application of fluorescence spectroscopy and resonant mirror biosensor to investigate the interactions of bovine milk xanthine oxidase and bovine erythrocyte copper, zinc-superoxide dismutase in crowded solutions. Four nonspecific high molecular mass crowding agents, poly(ethylene glycol) 2000 and 20,000, Ficoll 70, and dextran 70, and one low molecular mass compound, glycerol, are used. Superoxide dismutase shows a strong and macromolecular crowding agent concentration-dependent binding affinity to xanthine oxidase. Addition of high concentrations of such high molecular mass crowding agents increases the binding constant remarkably and thus stabilizes superoxide dismutase activity, compared to those in the absence of crowding agents. In contrast, glycerol has little effect on the binding constant and decreases superoxide dismutase activity over the same concentration range. Such a pattern suggests that the enhancing effects of polymers and polysaccharides on the binding are due to macromolecular crowding. Taken together, these results indicate that macromolecular crowding enhances the binding of superoxide dismutase to xanthine oxidase and is favorable to the function of superoxide dismutase.


Subject(s)
Cytoplasm/metabolism , Polymers/pharmacology , Superoxide Dismutase/metabolism , Xanthine Oxidase/metabolism , Animals , Cattle , Cytoplasm/chemistry , Cytoplasm/drug effects , Dextrans/pharmacology , Ficoll/pharmacology , Glycerol/pharmacology , Kinetics , Polyethylene Glycols/pharmacology , Protein Binding/drug effects , Protein Denaturation/drug effects , Protein Renaturation/drug effects , Spectrometry, Fluorescence/methods , Superoxide Dismutase/chemistry , Xanthine Oxidase/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...